The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. - sprookjes - yvandenbroek - TriplyDB

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.

http://www.wikidata.org/entity/Q44797430

about

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 Mesalamine in the treatment and maintenance of remission of ulcerative colitis Mesalazine in inflammatory bowel disease: a trendy topic once again?Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?Impact of pain on health-related quality of life in patients with inflammatory bowel disease Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.Review article: aminosalicylates in inflammatory bowel disease.Systematic review: the use of mesalazine in inflammatory bowel disease.What's new: innovative concepts in inflammatory bowel disease.Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.Quality of life of patients with ulcerative colitis: past, present, and future.Therapeutic strategies for the management of ulcerative colitis.Mesalamine with MMX technology for the treatment of ulcerative colitis.Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.Extended-release mesalamine granules for ulcerative colitis.Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Once-daily mesalamine granules for ulcerative colitis.Histological healing in inflammatory bowel disease: a still unfulfilled promise.Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.Comparing histological activity indexes in UC.Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.

P2860

Q24185876-6281A489-FCAB-479E-8187-D0ED9D99FCBF Q24198024-95AD3DED-9B04-488E-8007-38E2C2C0B6BE Q24246220-C34BF004-3834-4ED6-BB72-480D59888C6C Q26798299-F97D7AD6-CF7C-470C-B721-871C20412F9A Q26865546-2009F522-ACEF-4349-B392-9DE10D083978 Q33779797-A49C49B4-40E9-4F38-B7B3-715ED78AC257 Q33868970-B384605B-6CE9-48EA-BE85-62EE382A6AA5 Q33960394-CFABA9ED-6D61-437D-A6AC-4EA874B04CF6 Q34273329-ACA52167-01E2-4C59-B9FE-E6E01E93888D Q35719665-AA2CB223-6412-4F00-9522-29DFE0E87317 Q35880396-79A6B4BF-028F-4FBE-A2E1-D00BF0A82845 Q36435889-BEC592E1-CF61-4F49-9020-60FBA7C08E56 Q36440535-BDB9A6BA-B5D3-42D1-A923-27669DD454B0 Q36578893-321B2E0F-9E0F-4416-8FFA-53BF4420D417 Q36589413-971065F1-2AB7-416A-BF36-1ED294A8B3DD Q36987080-ADCB63CC-A8FC-4327-9C65-996F12331440 Q37318035-B3D9E8CC-3236-4DC0-B586-8C21D1E186F5 Q37345925-47967814-1F7E-43DE-ADDA-A6E537E19564 Q37853364-BCD845AB-3FC5-436B-B559-1E6A8C60DDA3 Q37854596-E56E8F40-C69A-4AB4-8B8D-1744F85731E3 Q37859277-D88F6597-D42F-46E2-B15E-5938A49F9005 Q38056892-B592B3D5-2D47-4C0C-BE63-D7988EAEA2A7 Q39232253-50A82E7A-50B9-4FFF-8F3E-DBA4B8B48954 Q39977343-756F739A-5667-41AF-AA36-46F1D4979251 Q41891210-7257BDE2-ADA8-484D-AB23-3363E4294D7C Q42695266-1EFB6966-3078-4A12-9245-FF3360B5D5A7 Q42995730-61A08EB2-8C86-4789-A246-B697A0484D8D Q43240077-6D9BB710-905F-4043-930D-80BF3A715F4E Q44127727-B3B7AC48-A5E3-43E6-A73D-2880DF964C11 Q44999862-78CE4CF4-2336-46C7-80CC-903EEF8CBE76 Q45096828-5F8D3EA4-DF54-4A1D-89B3-A68B564CFF30 Q45192026-10E49E4A-5FFF-4F27-94B7-74D32424A4B1 Q46457587-7157C9D7-1757-462F-8EC3-4E8C87CE34E6 Q49883190-BD2CB5FA-79F0-4D2B-9B5E-7A18EF27A640 Q51051300-C743F22E-9C73-48A6-AE80-24EBC9A7CFDB Q51531712-76D177D5-F58A-44D8-B84D-E9F27277A884 Q55439079-8D0B381D-65FE-4A58-B5D9-8FA459298432

P2860

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.

http://www.wikidata.org/entity/Q44797430

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@en

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@nl

type

label

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@en

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@nl

prefLabel

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@en

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@nl

P1433

Q44797430-9C8AFB6C-A17C-4053-83DE-0BB4C62228BF

P1476

Q44797430-EF4737C8-CDE9-4DE2-B6BF-927DDE574E85

P2093

Q44797430-0948B3BD-6612-456C-9EC8-48897C8F3330

Q44797430-09A6A4C6-5B7F-476E-B127-F08B417AAE37

Q44797430-1E1F5F5B-8776-4198-A24D-58D402E6E1EC

Q44797430-20CE0B0B-FC5D-44EC-9D03-7CFE6EDB4707

Q44797430-4CA31D23-DED8-4A67-8762-0E934DBB292D

Q44797430-4E4131F4-0493-4B6B-BB86-8398AB3BC78F

Q44797430-6A1678AF-81CC-4112-889D-BE4253E57E84

Q44797430-712A452E-DE69-4639-A036-D12CF37658D3

Q44797430-7335568D-3DDB-4647-8D25-BE1FA19AD00B

Q44797430-8F7FF1C2-E116-40D5-93EF-082C70156EC2

P304

Q44797430-E1BDF3F6-28A6-4D7D-9CDF-370F6EFE26A7

P31

Q44797430-C9EC7221-7F96-4361-B3A8-CBC960855FD8

P356

Q44797430-17BAD62C-F312-4282-B82D-A437ABF50193

P407

Q44797430-EAA89AF0-2350-404B-8266-6B493E3D0DC8

P433

Q44797430-9BAE98AD-FA0B-4AEA-AF60-6615B683311E

P478

Q44797430-0CD9C1EF-D8B6-4EC2-93AE-574BA1DF8C17

P577

Q44797430-8DB78920-4CE7-4622-9736-021BF6B87463

P5875

Q44797430-985865B4-8E7F-46FE-B04C-8CF3693DDCD7

P698

Q44797430-492DA378-3900-4E74-9B8B-199E260758D2

P356

JCGH.2003.50006

P1433

Clinical Gastroenterology and Hepatology

P1476

The optimal dose of 5-aminosal ...... th newly developed mesalamine.

@en

P2093

Agotá Kovacs

http://www.w3.org/2001/XMLSchema#string

Gabriella Lengyele

http://www.w3.org/2001/XMLSchema#string

Horst Mlitz

http://www.w3.org/2001/XMLSchema#string

Janos Feher

http://www.w3.org/2001/XMLSchema#string

László Lakatos

http://www.w3.org/2001/XMLSchema#string

Manfred Stolte

http://www.w3.org/2001/XMLSchema#string

Marek Faszczyk

http://www.w3.org/2001/XMLSchema#string

Michael Vieth

http://www.w3.org/2001/XMLSchema#string

Oliver Mickisch

http://www.w3.org/2001/XMLSchema#string

Roland Greinwald

http://www.w3.org/2001/XMLSchema#string

P304

36-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JCGH.2003.50006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5332693

http://www.w3.org/2001/XMLSchema#string

P698

15017515

http://www.w3.org/2001/XMLSchema#string